Renal Cell Carcinoma Treatment Regimens
Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.
Kidney Cancer
RCC With Isolated Lymph Node Metastases Has Poor Prognosis After Surgery
Following nephrectomy for renal cell carcinoma with lymph node involvement, patients have a 5-year survival rate of only 28%, a new study found.
CheckMate 214: Long-Term Results Confirm Superiority of Nivolumab Plus Ipilimumab for mRCC
Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations.
Looking at Survival Differently in Patients With Metastatic Kidney Cancer
Conditional survival may more accurately assess prognosis than traditional survival for patients with metastatic kidney cancer, but the metric is not without its caveats.
Should Age Be a Barrier to Clinical Trial Participation for Older Patients With Metastatic Renal Cell Carcinoma?
A retrospective study compared older patients with mRCC with younger ones to determine if age and potential comorbidities is a barrier to clinical trial participation.
Cryoablation vs PN for pT1b RCC Predicts Greater Cancer Death Risk
Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a study found.
Guideline-Based Hematuria Evaluation May Up Risk of Secondary Cancers
Uniform use of computed tomography for hematuria workups marginally increases detection of urinary tract cancers while raising the risk for secondary cancers from imaging-associated radiation, researchers concluded.
Cytoreductive Nephrectomy Alone for mRCC Linked to Better Survival
Cytoreductive nephrectomy (CN) by itself for metastatic renal cell carcinoma is associated with a 43% decreased risk of death compared with CN plus targeted therapy.
PN, RN Offer Comparable Long-Term Survival for T1b RCC
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
Benefit Seen from Frontline Pembrolizumab Plus Axitinib in Patients With Intermediate- or Poor-Risk Advanced RCC
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
Next post in Kidney Cancer
